Oxford Biomedica Rebrands as OXB, Highlights Global CDMO Focus

• Oxford Biomedica has announced a rebranding initiative, adopting the new name OXB and a modernised visual identity.

• The rebrand underscores OXB’s transformation into a global pure-play cell and gene therapy CDMO, reflecting its commitment to high-quality viral vector development and manufacturing.

Oxford Biomedica has rebranded as OXB, unveiling a new visual identity that aligns with its evolution into a global pure-play cell and gene therapy CDMO. The updated branding highlights OXB’s focus on technical excellence, innovation, and consistent high-quality delivery across all stages of viral vector development and manufacturing.

The rebranding reflects the company’s shift towards a more agile and creative execution, while maintaining core values of accountability, professionalism, and teamwork. This change aims to enhance communication of OXB’s end-to-end services and its global operational capabilities.

Dr. Frank Mathias, CEO of OXB, stated, “The launch of our new brand identity reinforces OXB’s significant transformation into a leading pure-play cell and gene therapy CDMO. This rebranding is more than just a new look—it reflects the global nature of our operations and our deep commitment to the success of our clients’ drug development programmes.”